Dublin, July 17, 2026 (GLOBE NEWSWIRE) -- The "Royalty Rates in Pharmaceutical and Biotechnology Deals 2015-2026" has been added to ResearchAndMarkets.com's offering.
Royalty Rates in Pharmaceutical and Biotechnology Deals serves as a definitive guide, offering unparalleled insights into 1,567 licensing transactions in the pharmaceutical, biotechnology, and diagnostics sectors. It provides detailed information on royalty rates, license fees, upfront payments, milestone payments, and the licensed technologies themselves. This report provides an invaluable resource for professionals seeking a deeper understanding of the structure, trends, and financial terms associated with royalty-based agreements.
Key Insights
The report explores the dynamics of royalty-based partnerships, focusing on the financial and structural terms critical to commercialization. By reviewing actual agreements, it highlights how payments are structured, triggered, and negotiated - insights often unavailable in press releases or databases.
For smaller companies and dealmakers, this report sheds light on the intricacies of payment clauses and provides crucial guidance on navigating negotiations with potential partners.
What's Inside:
Trends and Insights
- Comprehensive review of royalty rate trends in pharmaceutical and biotechnology deals since 2015.
- An orientation on royalty clause structures and their integration into broader financial terms.
Detailed Analysis
- Exploration of companies disclosing royalty rates and those securing the highest royalty terms.
- Insight into contract documents that detail payment structures, rights granted, and other key terms.
Extensive Deal Listings
- A directory of royalty-disclosing deals organized by company, therapeutic area, stage of development, and technology type.
- Hyperlinked deal titles for quick access to contract details and, where available, the full agreement.
Why This Report Matters
This report is an essential tool for industry professionals, offering:
- Clause Breakdown: Analyze royalty clauses with real-life examples.
- Deal Insights: Discover and benchmark collaboration and licensing agreements.
- Access to Contracts: Evaluate real agreements for detailed insights.
- Efficiency: Save valuable research time with consolidated, actionable data.
Report Scope
This report provides an in-depth understanding of royalty rate trends and deal structures across leading life science companies globally. It includes:
Analysis of royalty rate trends in biopharma since 2015.
- Case studies of licensing deals with disclosed royalty rates.
- Comprehensive listings of royalty-disclosing deals by company, therapeutic area, and technology type.
- Access to licensing contracts with detailed financial and legal terms.
Available Listings and Features
Deals are organized by:
- Company A-Z
- Therapeutic area
- Technology type
- Headline value
Each listing links to an online version of the deal record, with full contract documents available where applicable.
Key Questions Addressed
- What are the agreed royalty rates and terms?
- How are rights, exclusivity, and payment structures negotiated?
- What are the terms for development, commercialization, and supply?
- How are audits, confidentiality, and disputes managed?
- What jurisdiction governs the agreement?
Who Should Use This Report?
This report is tailored for C-level executives, business development professionals, licensing managers, legal advisors, and anyone involved in pharmaceutical and biotechnology deal-making. It provides the tools needed to evaluate and negotiate royalty terms effectively while benchmarking against industry standards.
Companies Featured
- 4D Molecular Therapeutics
- Abbisko Therapeutics
- Acumen Pharmaceuticals
- Adaptimmune
- Akeso Biopharma
- Alnylam Pharmaceuticals
- Amgen
- AnHeart Therapeutics
- Apellis Pharmaceuticals
- Arcturus Therapeutics
- Ascendis Pharma
- AstraZeneca
- Avidity Biosciences
- Bavarian Nordic
- Beam Therapeutics
- BioCryst Pharmaceuticals
- BioNTech
- Blueprint Medicines
- BridgeBio Pharma
- Caribou Biosciences
- Centessa Pharmaceuticals
- Chiesi Farmaceutici
- Coherus Biosciences
- CRISPR Therapeutics
- Cytokinetics
- Denali Therapeutics
- Dragonfly Therapeutics
- Elektrofi
- Esperion Therapeutics
- Exscientia
- Fate Therapeutics
- Foghorn Therapeutics
- Galapagos
- Generate Biomedicines
- Genmab
- Gilead Sciences
- Halozyme Therapeutics
- Harmony Biosciences
- Ideaya Biosciences
- Immunome
- Innovent Biologics
- Intellia Therapeutics
- Ionis Pharmaceuticals
- Jazz Pharmaceuticals
- Kymera Therapeutics
- Legend Biotech
- Madrigal Pharmaceuticals
- Moderna
- Nurix Therapeutics
- Vertex Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/y4ly0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
